[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597096":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":90,"collaborators":92,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":12,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":127,"whyStopped":12,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Imperial College London","OTHER",[8,13,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Arm Schedule","NO_INTERVENTION","All sites will begin in the Control arm, with patients recruited to the Control Arm Schedule. Clinical investigations prior to treatment, during treatment, after surgery and during further treatment should be performed as per standard clinical practice and as clinically indicated. Each site will remain in the Control Arm Schedule for six months. There will be a transition month with no recruitment where training is undertaken. After the transition month patients are recruited to the Intervention Arm Schedule . Patients will be recruited to either the Control or Intervention arms dependent on which arm is in progress at the site at the time of recruitment. There will be no crossover of patients between the arms at any point.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention Arm Schedule","EXPERIMENTAL","During the transition month, all Radiologists involved in reporting rectal cancers for the MDT will be offered training in reporting of mrTDV. Results of the retrospective data analysis will be shared at the MDT teams stakeholder meeting to determine their optimum stage based preoperative treatment decision making policy. Every site will remain in the Intervention Arm Schedule for six months.\n\nPatients will be recruited to either the Control or Intervention arms dependent on which arm is in progress at the site at the time of recruitment. There will be no crossover of patients between the arms at any point.",[18],"Other: mrTDV",{"label":20,"type":10,"description":21,"interventionNames":12},"Retrospective cohort","Registration of all rectal cancer patients staged as non-metastatic in their site pre-treatment MDT from 1st January 2019 - 31st December 2019 should commence as soon as the site is issued the green light. The analysis of this data will be presented to their site MDT six months from the green light. Therefore, every effort should be made to complete the 2019 retrospective cohort registrations within the first three months of the trial start. We anticipate the average number of 2019 retrospective cohort patients treated for rectal cancer will be 20 per site.",[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":12},"mrTDV","The training of radiologists to implement specialised MRI reporting using the TDV staging system",[14],[28],{"name":29,"affiliation":5,"role":30},"Gina Brown, MD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":12,"email":36},"Caroline Martin","CONTACT","+44 (0) 7749 655 817","giclinicaltrials@imperial.ac.uk",[38,57,75],{"facility":39,"status":12,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Southampton General Hospital","Southampton","Hampshire","SO16 6YD","United Kingdom","UK",{"type":46,"coordinates":47},"Point",[48,49],-1.40428,50.90395,{"lat":49,"lon":48},[52,55],{"name":53,"role":34,"phone":12,"phoneExt":12,"email":54},"Site Principal Investigator","Nigel.D'souza@uhs.nhs.uk",{"name":56,"role":30,"phone":12,"phoneExt":12,"email":12},"Nigel D'Souza",{"facility":58,"status":12,"city":59,"state":60,"zip":61,"country":43,"countryCode":44,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"John Radcliffe Hospital","Oxford","Oxfordshire","OX3 9DU",{"type":46,"coordinates":63},[64,65],-1.25596,51.75222,{"lat":65,"lon":64},[68,70,72],{"name":53,"role":34,"phone":12,"phoneExt":12,"email":69},"nicholas.symons@ouh.nhs.uk",{"name":71,"role":30,"phone":12,"phoneExt":12,"email":12},"Nicholas Symons",{"name":73,"role":74,"phone":12,"phoneExt":12,"email":12},"Edward Horwell","SUB_INVESTIGATOR",{"facility":76,"status":12,"city":77,"state":78,"zip":79,"country":43,"countryCode":44,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Salisbury District Hospital","Salisbury","Wiltshire","SP2 8BJ",{"type":46,"coordinates":81},[82,83],-1.79569,51.06931,{"lat":83,"lon":82},[86,88],{"name":53,"role":34,"phone":12,"phoneExt":12,"email":87},"Graham.Branagan@salisbury.nhs.uk",{"name":89,"role":30,"phone":12,"phoneExt":12,"email":12},"Graham Branagan",{"type":91,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[93,96],{"name":94,"class":95},"NHS England","OTHER_GOV",{"name":97,"class":6},"Pelican Cancer Foundation","100597096","improving-diagnosis-and-treatment-for-patients-with-rectal-cancer-100597096",false,"NCT07054047","Improving Diagnosis and Treatment for Patients With Rectal Cancer","Improving the Prognostic Accuracy of Staging Rectal Cancer Using Magnetic Resonance Imaging (MRI) - Detected Tumour Deposits and Vascular Invasion (mrTDV) Instead of Tumour Nodal Metastasis (mrTNM)","MERCURY 3","Inclusion Criteria:\n\n1. Have a rectal cancer proven on biopsy or subsequent surgery\n2. Sites able to submit anonymised MRI staging scans, pathology and imaging reports for central review\n3. Aged 16 years or over\n\nExclusion Criteria:\n\n1. Have irresectable metastatic disease at time of initial staging\n2. Undergoing palliative treatment for Rectal Cancer\n3. Have a biopsy-proven rectal malignancy which is not adenocarcinoma\n4. Are contraindicated for MRI staging","ALL","16 Years","99 Years",{"count":110,"type":111},438,"ESTIMATED","INTERVENTIONAL",[114],"NA","The cancer stage information from scans guides pre-operative treatment and the type of surgery offered. The investigators are studying whether a new Magnetic Resonance Imaging (MRI) staging method can improve the accuracy of prognosis for patients diagnosed with rectal cancer. The investigators will provide consultant radiologists with the know-how to report MRI scans using this new method and compare this with the existing method. This study will test this by comparing how accurately the old versus new method predict the outcomes of patients. The existing method relies on radiologists determining if tumour has spread through the bowel wall or not and whether there are suspected malignant lymph nodes. The new method looks for tumour spread into the veins and whether or not there are tumour deposits. Our previous research has shown that the new method is much more accurate at predicting prognosis, but this finding needs to be verified by a larger multicentre study.\n\nThe investigators are also studying the patient journey, so the investigators can better understand patients' experiences and the impact that treatments have on their quality of life. The investigators wish to understand if improvements in the accuracy of prognosis from scans could change treatment decisions in future. The investigators will also compare the radiology scan prediction of prognostic factors by looking carefully at the tumour specimens.",[117],"GI Cancer",[119,120,121,122,123,124,125,126],"Shared decision making","Radiotherapy","Quality of Life","MRI Staging","MDT Decision Making","Histopathological Staging","Rectal Cancer","Preoperative staging","NOT_YET_RECRUITING","2025-06-26",{"date":130,"type":131},"2025-07-08","ACTUAL",{"date":133,"type":111},"2025-07-01",{"date":135,"type":111},"2031-05-31",{"name":5,"class":6},3]